Opaleye Management Inc. - Sep 19, 2022 Form 4 Insider Report for Tracon Pharmaceuticals, Inc. (TCON)

Role
10%+ Owner
Signature
Opaleye Management Inc., By: /s/ James Silverman, President
Stock symbol
TCON
Transactions as of
Sep 19, 2022
Transactions value $
$9,367
Form type
4
Date filed
9/19/2022, 07:00 PM
Previous filing
Sep 16, 2022
Next filing
Sep 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCON Common Stock, par value $0.001 per share Purchase $9.37K +5K +1.35% $1.87 375K Sep 19, 2022 By Managed Account. F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TCON Prefunded Warrants 1.89M Sep 19, 2022 Common Stock 1.89M $0.01 By Opaleye, L.P. F3, F4
holding TCON Prefunded Warrants 1.36M Sep 19, 2022 Common Stock 1.36M $0.01 By Opaleye, L.P. F3, F4
holding TCON Prefunded Warrants 2.21M Sep 19, 2022 Common Stock 2.21M $0.01 By Opaleye, L.P. F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
F2 This transaction was executed in multiple trades at prices ranging from $1.8567 to $1.90; the price reported above reflects the weighted average purchase price. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased.
F3 Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F4 The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock.